We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Method Detects Colon Cancer Earlier

By LabMedica International staff writers
Posted on 24 Sep 2013
Techniques that identify gene variations that have been linked to colon cancer, may soon allow doctors to diagnose the disease in the very first stages, potentially saving patients' lives.

There is a need to provide those people who refuse screening colonoscopy with highly sensitive alternative tests, but the main problems in the attempt to establish molecular assays for noninvasive detection of early cancer stages or even of cancer precursors, are the choice of the appropriate biomarkers.

Scientists at the University of Potsdam (Germany) analyzed 80 human colon tissue and 31 associated feces specimens from subjects that had undergone routine colonoscopy and histopathologic assessment. More...
They used a combination of two techniques to analyze genetic variations within the cancerous and precancerous human colon tissue samples. One technique was the Locked Nucleic Acid (LNA)-based, wild-type blocking (WTB) polymerase chain reaction (PCR), which suppressed normal DNA present in large quantities, and the other was the High-Resolution Melting (HRM), which enhanced the detection of genetic variations. The WTB-PCR was conducted on an Eppendorf Mastercycler gradient (Hamburg, Germany) and the LC 480 Gene Scanning Software (Roche Diagnostics; Mannheim, Germany) was applied for HRM analysis.

There were two genes that were most frequently mutated in patients with colorectal cancer: a mutated Adenomatous polyposis coli (APC) gene was found in 60% of the patients and 40% of the patients has a mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) gene. The two methods detected APC variations in 41 of the 80 samples and identified previously unknown variations in APC. The currently used direct sequencing technique only detected variations in 28 of the samples. When the scientists then analyzed 22 stool samples from patients with APC variations in their colon tissues and 9 control stool samples without APC variations, they successfully detected APC variations in 21 out of the 22 samples.

Bettina Scholtka, PhD, an assistant professor at the University of Potsdam and senior author of the study, said, “Tumor cells are released into stool from the surface of precancers and early-stage colon cancers, but detecting a cancer-initiating genetic mutation among a large quantity of normal DNA from a patient's stool is like looking for a needle in a haystack. By using our technique for examining a selection of genes that become mutated during the process of colon cancer formation, it is possible to detect the very first stage of colon cancer and even precancers in a stool sample.” The study was published in the September 2013 issue of the journal Cancer Prevention Research.

Related Links:
University of Potsdam
Eppendorf
Roche Diagnostics



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.